These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 29425306)

  • 1. Interferon Treatment Duration in Patients With Chronic Delta Hepatitis and its Effect on the Natural Course of the Disease.
    Yurdaydin C; Keskin O; Kalkan Ç; Karakaya F; Çaliskan A; Kabaçam G; Önder FO; Karatayli S; Karatayli E; Deda X; Bozkaya H; Bozdayi AM; Idilman R
    J Infect Dis; 2018 Mar; 217(8):1184-1192. PubMed ID: 29425306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the efficacy of 12 months and longer courses of interferon therapy for the treatment of chronic delta hepatitis: a retrospective cohort study.
    Soyer OM; Baran B; Ormeci AC; Gokturk S; Aydın E; Onel D; Gulluoglu M; Karaca C; Akyuz F; Demir K; Besisik F; Kaymakoglu S
    Postgrad Med; 2016 May; 128(4):432-8. PubMed ID: 27054544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.
    Keskin O; Wedemeyer H; Tüzün A; Zachou K; Deda X; Dalekos GN; Heidrich B; Pehlivan S; Zeuzem S; Yalçın K; Gürel S; Tabak F; Idilman R; Bozkaya H; Manns M; Yurdaydin C
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2342-49.e1-2. PubMed ID: 26044319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring.
    Manesis EK; Schina M; Le Gal F; Agelopoulou O; Papaioannou C; Kalligeros C; Arseniou V; Manolakopoulos S; Hadziyannis ES; Gault E; Koskinas J; Papatheodoridis G; Archimandritis AJ
    Antivir Ther; 2007; 12(3):381-8. PubMed ID: 17591028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy of Delta Hepatitis.
    Yurdaydin C; Idilman R
    Cold Spring Harb Perspect Med; 2015 Aug; 5(10):. PubMed ID: 26253093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of pegylated interferon-α treatment for 24 months in chronic delta hepatitis and predictors of response.
    Karaca C; Soyer OM; Baran B; Ormeci AC; Gokturk S; Aydin E; Evirgen S; Akyuz F; Demir K; Besisik F; Kaymakoglu S
    Antivir Ther; 2013; 18(4):561-6. PubMed ID: 22976528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-year interferon therapy with or without ribavirin in chronic delta hepatitis.
    Gunsar F; Akarca US; Ersoz G; Kobak AC; Karasu Z; Yuce G; Ilter T; Batur Y
    Antivir Ther; 2005; 10(6):721-6. PubMed ID: 16218171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of chronic delta hepatitis.
    Yurdaydin C
    Semin Liver Dis; 2012 Aug; 32(3):237-44. PubMed ID: 22932972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnosis and treatment of chronic hepatitis B and D. Hungarian national consensus guideline].
    Horváth G; Hunyady B; Gervain J; Lengyel G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I
    Orv Hetil; 2014 Mar; 155 Suppl():25-36. PubMed ID: 24631887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis.
    Kabaçam G; Dalekos GN; Çakaloğlu Y; Zachou K; Bock T; Erhardt A; Zeuzem S; Tabak F; Yalçin K; Bozdayi AM; Dienes HP; Bozkaya H; Manns M; Wedemeyer H; Yurdaydin C
    Turk J Gastroenterol; 2012; 23(5):560-8. PubMed ID: 23161302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Discussions the therapy strategy of chronic hepatitis B by analyzing the therapeutics course of a chronic hepatitis B patient].
    Yang LQ
    Zhonghua Gan Zang Bing Za Zhi; 2009 Sep; 17(9):709-10. PubMed ID: 19785967
    [No Abstract]   [Full Text] [Related]  

  • 12. [The role and possibilities of natural interferon treatment in chronic hepatitis C: experience with natural interferon treatment for patients barred from combined antiviral therapy because of the STOP rule].
    Horváth G; Tolvaj G; Halász T; Stotz G
    Orv Hetil; 2007 Aug; 148(33):1545-50. PubMed ID: 17686672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients.
    Idilman R; Cinar K; Seven G; Bozkus Y; Elhan A; Bozdayi M; Yurdaydin C; Bahar K
    J Viral Hepat; 2012 Mar; 19(3):220-6. PubMed ID: 22329377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta.
    Heidrich B; Yurdaydın C; Kabaçam G; Ratsch BA; Zachou K; Bremer B; Dalekos GN; Erhardt A; Tabak F; Yalcin K; Gürel S; Zeuzem S; Cornberg M; Bock CT; Manns MP; Wedemeyer H;
    Hepatology; 2014 Jul; 60(1):87-97. PubMed ID: 24585488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response.
    Niro GA; Smedile A; Fontana R; Olivero A; Ciancio A; Valvano MR; Pittaluga F; Coppola N; Wedemeyer H; Zachou K; Marrone A; Fasano M; Lotti G; Andreone P; Iacobellis A; Andriulli A; Rizzetto M
    Aliment Pharmacol Ther; 2016 Sep; 44(6):620-8. PubMed ID: 27443972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA.
    Shiratori Y; Yokosuka O; Nakata R; Ihori M; Hirota K; Katamoto T; Unuma T; Okano K; Ikeda Y; Hirano M; Kawase T; Takano S; Matsumoto K; Ohashi Y; Omata M
    Hepatology; 1999 May; 29(5):1573-80. PubMed ID: 10216145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up.
    Castelnau C; Le Gal F; Ripault MP; Gordien E; Martinot-Peignoux M; Boyer N; Pham BN; Maylin S; Bedossa P; Dény P; Marcellin P; Gault E
    Hepatology; 2006 Sep; 44(3):728-35. PubMed ID: 16941695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B.
    Chuaypen N; Posuwan N; Payungporn S; Tanaka Y; Shinkai N; Poovorawan Y; Tangkijvanich P
    Liver Int; 2016 Jun; 36(6):827-36. PubMed ID: 26678018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of chronic hepatitis D patients with pegylated interferon: a real-world experience.
    Abbas Z; Memon MS; Mithani H; Jafri W; Hamid S
    Antivir Ther; 2014; 19(5):463-8. PubMed ID: 24423484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current management of delta hepatitis.
    Rizzetto M
    Liver Int; 2013 Feb; 33 Suppl 1():195-7. PubMed ID: 23286865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.